Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App





Werfen Offers In-Booth Instrument Demonstrations and Educational Workshop

By LabMedica International staff writers
Posted on 22 Jul 2023

Werfen (Barcelona, Spain) is offering in-booth demonstrations of its point-of-care and laboratory instruments, reagents, and data management solutions at AACC 2023. More...

The company is also hosting an educational workshop focusing on the prevalence and impact of pre-analytical errors in point-of-care blood gas testing. Werfen is also hosting a press conference at the AACC to introduce and explain the company’s recent acquisition of Immucor, Inc. (Norcross, GA, USA).

Werfen provides a comprehensive and integrated range of products and services. From intensive care units to operating rooms, emergency departments to interventional radiology suites and cardiac catheterization labs, and central and satellite laboratories, the company’s testing solutions are designed to deliver quality results, quickly and simply, irrespective of the setting. At AACC 2023, Werfen is offering instrument demonstrations its wide range of systems, including the ACL TOP Family 50 Series, HemoCell Specialized Lab Automation, HemosIL assays, HemoHub Intelligent Data Manager; GEM Premier 5000, GEM Premier ChemSTAT, GEM Hemochron 100, ROTEM sigma, VerifyNow, GMweb Plus 500, Aptiva, BIO-FLASH, QUANTA-Lyser, QUANTA-Link; Echo Lumena, and NEO Iris. The company is also offering a virtual reality experience featuring customized layouts for HemoCell Lab Automation.

At AACC 2023, senior leaders from Werfen will introduce and explain the company’s recent acquisition of Immucor, an in vitro diagnostic company with strong global leadership in the clinical areas of transfusion and transplant. With the integration of Immucor, Werfen has expanded its presence in specialized diagnostics with seven technology centers and more than 7,000 employees worldwide. The company will continue to operate directly in 34 countries, and in more than 100 territories through distributors. Most importantly, Werfen can now offer its customers an even broader portfolio of products and solutions across hospital acute care settings, and contribute to the care of more patients around the world.

Related Links:
Werfen 
Immucor, Inc. 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.